Cranberry Extract Wins "Technology Innovation Award"
Release time:
2020-07-22
Peak Health Achievements Won Industry Praise
Cranberry Extract Won "Technology Innovation Award"
News 6# At the NEX China World Natural Extract China Exhibition held in Shanghai in mid-November, the cranberry extract focused on by Jianfeng Health Technology Company won the 2019 Plant Extract Technology Innovation Award issued by China Chamber of Commerce for Import and Export of Medicines and Health Products (hereinafter referred to as "Medical Insurance Chamber of Commerce").
Medical Insurance Chamber of Commerce launched the selection and display of innovative products of Chinese plant extracts, aiming to set an example for the industry, promote innovation and promote the development of the industry. Spike Health stands out from the many candidate units, due to the deep cultivation of cranberry extract products. Starting from the launch of 2015 products to the market, Jianfeng Health has chosen to import raw materials from the world's largest cranberry farm to produce high-quality products (above total proanthocyanidins 95% are rich in special A proanthocyanidins); From commissioned processing to the establishment of intelligent and automatic production lines such as membrane filtration and column chromatography, the efficient transformation of production process control has been completed. Quality control index from only total proanthocyanidins, to be the first in the industry to be in line with international standards, the index of A proanthocyanidins was introduced, a more stable and economical DMAC detection method was optimized, and HPLC characteristic spectrum was established in the aspect of authenticity identification. Products also range from single extract raw materials to functional formula food series. Due to the continuous exploration in cranberry production technology, detection technology, product formula innovation and other aspects, peak health 2017 was named "cranberry extract quality supplier", and 2018 became the only drafting unit for the formulation of cranberry extract group standards of the medical insurance chamber of commerce.
At the 2019 CPhI China World Pharmaceutical Raw Materials China Exhibition held concurrently with the NEX China World Natural Extract China Exhibition, Dr. Li Wende, Chief Scientist and Deputy General Manager of Spike Health, was also invited to give a roadshow on "Innovation in Cranberry Extract Production Technology", expanding the influence of Spike Health Cranberry Extract in domestic and overseas markets. (Yang Hao Yao Lili)
News Link:
Cranberry, also known as Cranberry and Cranberry. Mainly produced in the cold North American wetlands, is one of the three major fruits in North America, but also the local traditional health food. Cranberry is rich in proanthocyanidins and natural flavonoids, which has antioxidant properties and protects cardiovascular system health. In particular, its A family proanthocyanidins have the effects of preventing urinary tract infection, eliminating Helicobacter pylori, preventing stomach diseases and inhibiting oral bacteria.
0 HPLC , high performance liquid chromatography, a precision instrument detection technology, has the advantages of high pressure, high speed, high efficiency, high sensitivity, wide application range, repeated use of chromatographic column, no damage to samples, easy recovery, etc. It has important applications in chemistry, medicine, industry, agronomy, commodity inspection, legal inspection and other disciplines.
0 DMAC , is an English abbreviation for color reagent, and also represents an industry standard accurate detection method for proanthocyanidins.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page